市场调查报告书
商品编码
1368684
人类微生物组市场规模 - 按部位(消化道、肺)、应用(治疗、诊断)、疾病(传染病、胃肠道疾病)、产品(药物、诊断测试、益生菌)和全球预测 2023-2032Human Microbiome Market Size - By Site (Digestive Tract, Lung), Application (Therapeutics, Diagnostics), Disease (Infectious Diseases, Gastrointestinal Diseases), Product (Drugs, Diagnostic Tests, Probiotics) & Global Forecast 2023-2032 |
在全球优先考虑该领域研究的资助计划和政府计划不断增加的推动下,2023 年至 2032 年间,全球人类微生物组市场份额将以 25.4% 的复合年增长率增长。微生物组研究的财政支持可加速科学进步,从而促进创新疗法和诊断工具的开发。
2022 年7 月,杜蒙特-加州大学洛杉矶分校移植中心获得了总计1150 万美元的联邦政府拨款,用于支持研究工作,其目标是延长捐赠器官的生存能力并提高移植受者的整体健康状况和寿命。这些赠款一笔由美国国立卫生研究院提供,另一笔由国防部提供,致力于提高肝臟移植以及手部和脸部移植的效果。这些投资吸引了製药和生物技术公司,促进了合作并扩大了市场。强调了解微生物组在健康和疾病中的作用,使人类微生物组产业在未来几年显着成长。
整个人类微生物组市场根据地点、应用、疾病、产品和地区进行划分。
到 2032 年,诊断领域可能会以可观的增长率扩张。人们日益认识到微生物组在健康和疾病中发挥的重要作用,从而推动了对人类微生物组诊断的需求。研究人员和医疗保健专业人员越来越认识到,个别微生物组的组成可以为各种健康状况提供有价值的见解,包括胃肠道疾病、自体免疫疾病,甚至心理健康问题。因此,人们对基于微生物组的诊断越来越感兴趣,从而产生了对先进测试和分析方法的需求。
到 2032 年,益生菌细分市场可能会占据一定的人类微生物组产业份额。人类微生物组益生菌由于其支持肠道健康和整体福祉的潜力而需求量很大。这些益生菌含有有益微生物,可以帮助维持肠道微生物组的平衡,而肠道微生物组与从消化到免疫功能等健康的各个方面越来越相关。寻求自然方法来改善健康的消费者正在转向微生物益生菌,这为这些产品创造了强劲的市场需求。
由于多种因素,亚太地区人类微生物组产业正在不断扩张。人们越来越认识到微生物组在健康中发挥的关键作用,这推动了对基于微生物组的产品和服务的需求。此外,慢性健康状况的增加激发了人们对微生物组研究和治疗的兴趣。此外,该地区不断增加的医疗基础设施和研究投资进一步促进了亚太地区人类微生物组产业的成长。
Global Human Microbiome Market share will grow at 25.4% CAGR between 2023 and 2032, driven by the increasing funding initiatives and government programs worldwide prioritizing research in this field. Financial support for microbiome research accelerates scientific advancements, leading to the development of innovative therapies and diagnostic tools.
In July 2022, the Dumont-UCLA Transplant Center secured a combined $11.5 million in federal government grants to support research endeavors with the goal of extending the viability of donated organs and enhancing the overall health and longevity of transplant recipients. These grants, one provided by the National Institutes of Health and the other by the Department of Defense, are dedicated to advancing the outcomes of liver transplantation and hand and face transplantation. These investments attract pharmaceutical and biotechnology companies, fostering collaborations and expanding the market. The emphasis on understanding the role of the microbiome in health and disease positions the human microbiome industry for significant growth in the coming years.
The overall human microbiome market is segregated based on site, application, disease, product, and region.
The diagnostics segment could expand at a decent growth rate through 2032. The demand for human microbiome diagnostics is propelled by the growing awareness of the significant role the microbiome plays in health and disease. Researchers and healthcare professionals are increasingly recognizing that the composition of an individual's microbiome can provide valuable insights into various health conditions, including gastrointestinal disorders, autoimmune diseases, and even mental health issues. As a result, there's a rising interest in microbiome-based diagnostics, creating a demand for advanced testing and analysis methods.
The probiotics segment could capture a modest human microbiome industry share by 2032. Human microbiome probiotics are in high demand due to their potential to support gut health and overall well-being. These probiotics contain beneficial microorganisms that can help maintain a balanced gut microbiome, which is increasingly linked to various aspects of health, from digestion to immune function. Consumers seeking natural ways to improve their health are turning to microbiome probiotics, creating a strong market demand for these products.
Asia Pacific human microbiome industry is expanding due to several factors. A growing awareness of the pivotal role the microbiome plays in health is driving demand for microbiome-based products and services. Besides, the rise in chronic health conditions has spurred interest in microbiome research and therapies. Moreover, the region's increasing healthcare infrastructure and research investments further facilitate the growth of the human microbiome industry in the Asia Pacific.